Dual GIP/GLP-1 agonist for comprehensive metabolic support.
Compound_Description
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative peptide combines the actions of two incretin hormones into a single molecule, offering enhanced metabolic effects compared to single-receptor agonists.
The dual agonist approach provides complementary mechanisms of action. GLP-1 receptor activation supports glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite. GIP receptor activation enhances insulin secretion, improves insulin sensitivity, and may have additional effects on lipid metabolism and adipose tissue.
Clinical research has demonstrated that Tirzepatide produces superior outcomes compared to GLP-1 agonists alone in multiple parameters, including body weight reduction, glycemic control, and metabolic improvements. The SURPASS and SURMOUNT clinical trial programs have established the efficacy and safety profile of this dual agonist.
Tirzepatide's once-weekly administration and sustained effects make it a significant advancement in metabolic research peptides.
Research_Applications
- check_circle Dual incretin research
- check_circle GIP receptor studies
- check_circle GLP-1 receptor research
- check_circle Metabolic syndrome research
- check_circle Body composition studies
Scientific_Studies
SURMOUNT-1 Trial Results
Jastreboff AM et al. published SURMOUNT-1 results showing significant weight reduction with Tirzepatide.
SURPASS Clinical Program
Frías JP et al. comprehensive SURPASS trial results for Tirzepatide in diabetes.
Dual Agonist Mechanism
Research on the mechanism of action of dual GIP/GLP-1 receptor agonists.
Research Use Only
This product is for laboratory research purposes only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.